ArticleCancer immunology research2021
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Cancer immunology research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05867004 (Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma), which is not on this map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- The Phospholipid Bis(monoacylglycero)Phosphate Confers Antitumour Immunogenicity to Exosomes Secreted by Dendrogenin A, Which Activates Its Biosynthesis in Tumour Cells.Journal of extracellular vesicles · 2026Article
- An update on schistosomicide and tumoricide in the future: arachidonic acid.Lipids in health and disease · 2025Review
- Inflammation related proteins and PLCG1 may contribute to papillary thyroid carcinoma risk through a potential regulatory axis.Discover oncology · 2025Article
- SMPD2 affects the prognosis of cancer patients by mediating lipid metabolism and the immune microenvironment.Discover oncology · 2025Article
- The role of exosomal PD-L1 in NSCLC immunotherapy.Immunotherapy · 2025Review
- Serum and plasma sphingolipids as biomarkers of chemotherapy-induced cardiotoxicity in female patients with breast cancer.Journal of lipid research · 2025Article
- Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.Molecular cancer · 2025Review
- Neutral sphingomyelinase 2: A promising drug target for CNS disease.Advances in pharmacology (San Diego, Calif.) · 2025Review
- SMPD3 as a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma.International journal of genomics · 2025Article
- Contribution of Keratinocytes in Skin Cancer Initiation and Progression.International journal of molecular sciences · 2024Review
- METTL5 promotes gastric cancer progressionWorld journal of gastrointestinal oncology · 2024Article
- Proteomic Analysis Highlights the Impact of the Sphingolipid Metabolizing Enzyme β-Galactosylceramidase on Mitochondrial Plasticity in Human Melanoma.International journal of molecular sciences · 2024Article
- Ceramide metabolism alterations contribute to Tumor Necrosis Factor-induced melanoma dedifferentiation and predict resistance to immune checkpoint inhibitors in advanced melanoma patients.Frontiers in immunology · 2024Article
- Reprogramming of Lipid Metabolism Mediates Crosstalk, Remodeling, and Intervention of Microenvironment Components in Breast Cancer.International journal of biological sciences · 2024Review
- Article
- Engineered Lipidic Nanomaterials Inspired by Sphingomyelin Metabolism for Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- The Pro-Oncogenic Sphingolipid-Metabolizing Enzyme β-Galactosylceramidase Modulates the Proteomic Landscape in BRAF(V600E)-Mutated Human Melanoma Cells.International journal of molecular sciences · 2023Article
- Functional roles of sphingolipids in immunity and their implication in disease.Experimental & molecular medicine · 2023Review
- Single-cell sequencing analysis related to sphingolipid metabolism guides immunotherapy and prognosis of skin cutaneous melanoma.Frontiers in immunology · 2023Article
- Extracellular Vesicles and Their Roles in the Tumor Immune Microenvironment.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 5 institutions in 2 countries.
Anne Montfort *INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Florie Bertrand *INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Julia Rochotte *INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Julia GilhodesInstitut Universitaire du Cancer (IUCT-O), Toulouse, France.
Thomas FilleronInstitut Universitaire du Cancer (IUCT-O), Toulouse, France.ORCID 0000-0003-0724-0659
Jean MilhèsINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Carine DufauINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Caroline ImbertINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Joëlle RiondINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.ORCID 0000-0002-6281-2376
Marie TosoliniINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.ORCID 0000-0001-5278-5952
Christopher J ClarkeStony Brook Cancer Center, and Department of Medicine, Stony Brook University, New York, New York.ORCID 0000-0002-4855-522X
Florent DufourINSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.
Andrei A ConstantinescuINSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.
Nilton De França JuniorINSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.ORCID 0000-0003-2142-2619
Virginie GarciaINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Michel RecordINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Pierre CordelierINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.ORCID 0000-0003-2096-7967
Pierre BroussetINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.ORCID 0000-0002-8629-3291
Philippe RochaixINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.ORCID 0000-0001-6238-1599
Sandrine Silvente-PoirotINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.ORCID 0000-0003-2245-9069
Nicole ThervilleINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.ORCID 0000-0002-7068-1361
Nathalie Andrieu-AbadieINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.ORCID 0000-0003-2698-1970
Thierry LevadeINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Yusuf A HannunStony Brook Cancer Center, and Department of Medicine, Stony Brook University, New York, New York.ORCID 0000-0003-3349-3369
Hervé BenoistINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Nicolas MeyerINSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Olivier MicheauINSERM, UMR1231, Laboratoire d'Excellence LipSTIC, Dijon, France.ORCID 0000-0001-8499-7984
Céline Colacios *INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.
Bruno Ségui *INSERM UMR 1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France. bruno.segui@inserm.fr.
Inserm · FRUniversité Toulouse III - Paul Sabatier · FRCentre National de la Recherche Scientifique · FRInstitut universitaire du cancer de Toulouse Oncopole · FRStony Brook University · US
Funding
Sphingolipids in Cancer Therapy and AngiogenesisP01CA097132 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI YUSUF AWNI HANNUN · 2003 to 2026
$30.8MNeutral Sphingomyelinases and Bioactive CeramidesR35GM118128 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI HANNUN, YUSUF AWNI · 2016 to 2025
$7.9MSPHINGOMYELIN TURNOVER AND CELLULAR REGULATIONR01GM043825 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HANNUN, YUSUF AWNI · 1991 to 2006
$2.2MNCI NIH HHS P01 CA097132NIGMS NIH HHS R01 GM043825NIGMS NIH HHS R35 GM118128
Abstract
Dysregulation of lipid metabolism affects the behavior of cancer cells, but how this happens is not completely understood. Neutral sphingomyelinase 2 (nSMase2), encoded by
Indexed as
AnimalsAntineoplastic AgentsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunityImmunotherapyMelanomaMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorSphingomyelin PhosphodiesteraseTh1 CellsAntineoplastic AgentsProgrammed Cell Death 1 ReceptorSMPD3 protein, humanSmpd3 protein, mouseSphingomyelin Phosphodiesterase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05867004ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.